Send the following on WhatsApp
Continue to ChatCanakinumab in patients with systemic juvenile idiopathic arthritis and active systemic features: results from the 5-year long-term extension of the phase III pivotal trials - https://avesis.istanbul.edu.tr/yayin/d5e90f24-2e77-4565-8318-b0b37c676319/canakinumab-in-patients-with-systemic-juvenile-idiopathic-arthritis-and-active-systemic-features-results-from-the-5-year-long-term-extension-of-the-phase-iii-pivotal-trials